RxBlog

  • rxblog
    RxBlog is a simple weblog dedicatd to pharmaceutical news and drug information.
  • RxBlog (tm) com/net
    Is a Trademark

Pages

Sponsor Media

Simple

Sponsor Links

RxBlog Blogroll


  • rxblog.com qr code
  • Pfizer
    Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment.
  • Schering-Plough
    We aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.
  • Wyeth
    Wyeth pharmaceutical company brings health care products, medicines and vaccines that aim to improve lives and deliver value to customers.
  • Novartis
    Novartis is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and to enhance the quality of life.
  • GlaxoSmithKline
    Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
  • AstraZeneca
    One of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas.
  • Merck
    A global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.
Subscribe to this blog's feed

« Risk of Breast Cancer Among Premenopausal Women and Red Meat Intake. | Main | Stem cell cure hope for diabetes »

Human Genome reports positive trial of lupus treatment.

Human Genome Sciences said a 76-week Phase II trial of its lupus treatment LymphoStat produced positive results, reducing disease activity and appearing to be well-tolerated by patients. The percentage of patients who met the trial's primary endpoint for Phase III trials rose from 46% after 52 weeks to 56% after 76 weeks, the Rockville, Md. biotechnology company said.

» Search Healthcare-Specific Tags: LymphoStat - Human Genome - Lupus
» Human Genome Sciences

Comments